Better Access
Better Healthcare

We improve global healthcare through better access to medicine.

  • 00Day(s)
  • 00Hour(s)
  • 00Minute(s)

EAHP CONGRESS

Meet us at the 29th EAHP Congress on Stand D73 from 12-14 March 2025 in Copenhagen

11
Global locations
1500
Employees
35
Countries supplied in 2024

Visit the different business units of Abacus Medicine Group

Abacus Medicine is firmly established among the market leaders in the European parallel distribution industry.

Abacus Medicine Clinical Trial Services provides comparator sourcing services to support the running of clinical trials for pharma companies.

Abacus Medicine Pharma Services provides end-to-end commercialisation services to advance access to rare disease medicines in Europe.

Originalis is a parallel distributor of medicine operating in Germany and Ireland, providing customers with more options to choose from.

Pluripharm is a leading wholesaler in the Netherlands and offers a full line of medicines, medical devices and services to a range of customers.

We are innovative, dedicated and we care.

The Abacus Medicine Group is built on a strong purpose. When we compete in the market, we help lower the prices on life-critical medicines so that they become more widely available.

“The Abacus Medicine Group is a business. We operate commercially, and our activities provide jobs, careers and livelihoods for thousands of people in dozens of countries. But we are more than that. When we compete in the market, we help life-critical medicines become more widely available. This gives us a purpose beyond ourselves and is something we can be proud of.”

Flemming Wagner, CEO & majority shareholder

A career in the Abacus Medicine Group

Join an ambitious and diverse company.
We are always looking for new and dedicated colleagues.

Latest News

Abacus Sustainability Report 2024

Sustainability Report 2024: 20 years of care and contribution

In our Sustainability Report 2024, we demonstrate how we increasingly recognise the crucial link between ESG and business performance, highlighting...
Abacus Annual Report 2024

Abacus Medicine Group celebrates record year

In 2024, the Abacus Medicine Group celebrated 20 years of strong, organic growth. Revenue grew 23% to EUR 1,487 million,...

The Abacus Medicine Group Today Announces the Nomination of Two New Members of The Board of Directors

Alette Verbeek and Sharon Curran are being nominated by the main shareholders, Wagner Family Holding ApS (approx. 58% ownership) and...